PURPOSE: To obtain a medicine for oral administration effective for hepatic failure, capable of extremely improving solubility of DDB and enhancing treating effects, containing mixed pulverized powder or solid dispersion powder of DDB and a dissolution promoting substance. CONSTITUTION: This medicine ...
PREPARATION OF SOLID DRUG FOR ORAL ADMINISTRATION PURPOSE:To obtain a solid drug for oral administration having shielded disagreeable taste in high efficiency, by adding an organic solvent to a powdery mixture of a drug and a substance capable of shielding disagreeable taste, granulatin... N Yasuhi...
OBJECTIVE: The purpose of this study was to assess the status of 156 adult volunteers with major depressive disorder (MDD) 6 months after completion of a s... M Babyak,JA Blumenthal,S Herman,... - 《Psychosomatic Medicine》 被引量: 1706发表: 2000年 GENDER DIFFERENCES IN SUBSTANCE USE DIS...
Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma. The purpose of this phase II trial was to confirm the activity of this schedule of etoposide in a selected group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's...
PURPOSE: To obtain a lyophilized composition quickly dissolvable on contact with animal or human saliva or water for its oral administration, by freezing a hydrated composition comprising a gel or bubbly substance and a curing agent therefor and by bringing the frozen composition into contact with ...
Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma. The purpose of this phase II trial was to confirm the activity of this schedule of etoposide in a selected group of heavily pretreated patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's...
PREPARATION OF ORAL ADMINISTRATION 专利名称：PREPARATION OF ORAL ADMINISTRATION 发明人：OZAWA YASUO,YAMADA KENJI,FURUYA ATSUSHI,AKIMOTO MASAYUKI 申请号：JP17693289 申请日：19890707 公开号：JPH0341023A 公开日：19910221 专利内容由知识产权出版社提供 摘要：PURPOSE:To obtain an orally administrative antitussive ...
FDA = Food and Drug Administration; VTE = venous thromboembolism; CAD = coronary artery disease; PAD = peripheral arterial disease; CrCl = creatinine clearance; N/A = not approved for this indication. Table 2. Pharmacokinetic and Pharmacodynamic properties of direct oral Anticoagulants (Do...
PURPOSE: The reported incidence of osteonecrosis of the jaw (ONJ) ranges from 0.94% to 18.6%. This cohort study aimed to calculate the incidence of and ide... K Vahtsevanos,A Kyrgidis,E Verrou,... - 《Journal of Clinical Oncology Official Journal of the American Society of Clinical Onco...
PURPOSE:To provide the titled preparation containing bis[cyclo(histidylhistidine)] copper salt complex as an active component, effective in removing active oxygen and preventing the formation of lipid peroxide in the living body, exhibiting prolonged effect by oral administration and useful as a remedy...